SCHEMBL1946641

SCHEMBL1946641

c1cncc(CNc2nn3cc(-c4ccsc4)nc3s2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 5/20 0.48
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
RAB9A P51151 2/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
CD274 Q9NZQ7 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946536 0.88 TP53 (0.47) FYNALDH1A1SMN1; SMN2KDM4ETDP1
SCHEMBL1947763 0.87 FYN (0.56) FYNALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL1944359 0.87 FYN (0.50) FYNSMN1; SMN2KDM4ERAB9AROCK2
SCHEMBL2253531 0.85 CCNE1 (0.51) FYNALDH1A1SMN1; SMN2KDM4ETDP1
SCHEMBL1944472 0.85 FYN (0.64) FYNALDH1A1SMN1; SMN2KDM4ETDP1
SCHEMBL1943954 0.83 PIM1 (0.50) FYNALDH1A1SMN1; SMN2KDM4ETDP1
SCHEMBL1944440 0.83 FYN (0.62) FYNALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL1945365 0.82 FYN (0.50) FYNALDH1A1SMN1; SMN2KDM4ETDP1
SCHEMBL1945338 0.82 GSK3B (0.50) FYNALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL1944669 0.82 F2RL3 (0.46) FYNSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R FYN 1977/4885ALDH1A1 416/4885SMN1; SMN2 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.